Physician profile
William J Pevsner
NPI 1679758171
$6,610.79
in general payments reported to CMS, 2019-2025
34 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $553 · 2021: $1,337 · 2022: $1,158 · 2023: $641 · 2024: $1,122 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,017.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $907.70 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $674.43 | 2020-2025 | Jardiance |
| Abbvie INC. | $597.63 | 2021-2025 | |
| Novo Nordisk INC | $546.56 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $519.84 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $298.61 | 2020-2025 | Nexletol |
| Pfizer INC. | $187.09 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $178.73 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.71 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $157.83 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $125.54 | 2019-2022 | |
| Lilly USA, LLC | $121.21 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $116.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $106.70 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.29 | 2023-2025 | Xifaxan, Trulance |
| Allergan, INC. | $93.30 | 2019-2020 | |
| Amgen INC. | $90.02 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $74.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $68.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.94 | 2022-2024 | |
| Glaxosmithkline, LLC. | $64.17 | 2022-2024 | Arexvy, Shingrix |
| Horizon Therapeutics Plc | $58.79 | 2020-2021 | |
| Lundbeck LLC | $46.18 | 2025 | Rexulti |
| Exact Sciences Corporation | $39.50 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.81 | 2023 | Gvoke Hypopen |
| Bausch Health US, LLC | $22.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.94 | 2019 | |
| Antares Pharma, INC. | $21.40 | 2019 | |
| Boston Scientific Corporation | $18.31 | 2020 | |
| Astellas Pharma US INC | $18.07 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.97 | 2023 | Quviviq |
| Cequr Corporation | $15.90 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pevsner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.